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CHAPTER I 
 
  
INFLAMMATION  
 
Inflammation is a defense reaction to an injury of different type 
(bacterial, physical, chemical etc.), whose ultimate purpose is the 
elimination of injurious cause and the restoration of tissue integrity. 
Signs and symptoms of inflammation depend upon the interaction among 
different cells and mediators into the damaged tissue.  
Cells involved are either leukocytes recruited from circulation and those 
resident into the tissue, such as mast cells, macrophages, but also stromal 
cells, such as endothelial cells, fibroblasts, smooth muscle. Inflammatory 
mediators are produced by all cells involved, stromal and recruited.  
Depending on their biochemical properties, inflammatory mediators may 
be classified into seven groups: vasoactive amines, vasoactive peptides, 
complement components, lipid mediators, cytokines, chemokines and 
proteolytic enzymes (Medzhitov et al., 2008). 
Biogenic amines are preformed mediators, stored into mast cell and 
platelet granules released following activation. Their main effect is on 
vasculature, where they cause increased vascular permeability and 
vasodilatation. Vasoactive peptides can be stored in secretory granules, 
such as substance P, or generated by proteolysis, such as bradykinin; 
these peptides also affect vasculature and have pro-algesic effect. 
Complement fragments, such as C3a, C4a and C5a promote cell 
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recruitment into the damaged tissue. Lipid mediators, eicosanoids and 
platelet activating factors (PAF), derive from arachidonic acid as 
products of cyclooxygenases (prostaglandins and thromboxane) or as 
products of lipooxygenase (leukotrienes and lipoxins), or from 
lysophosphatidic acid (PAF). Prostaglandins, leukotrienes and PAF all 
participate to cause signs of inflammations, vasodilatation or smooth 
muscle contractions, cell recruitment, pain, fever; on the other hand, 
lipoxins are involved in resolution of inflammation and tissue repairing 
processes. Proinflammatory cytokines (IL-1, IL-6, TNFα and many 
others) have several roles in inflammatory response, they activate cells 
and induce acute phase response; antinflammatory cytokines, such as IL-
10, can inhibit the production of inflammatory cytokines and down-
regulates previously activated cells. Chemokines are responsible of cell 
recruitment into the damaged tissue. Proteolytic enzymes, 
metalloproteinases, cathepsins, elastin, have a role in degrading 
extracellular matrix, in tissue remodeling and leukocyte migration (Pober 
and Sessa, 2007; Barton et al., 2008). 
In other words, all cells, either recruited or stromal participate actively to 
the inflammatory process through the production of soluble mediators 
responsible, in turn, for other cell recruitment. In this way the 
inflammatory process, with its actors, cells and mediators, possess a 
great“self-amplifying” ability (Figure 1).  
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Over the years the list of soluble mediators involved in the inflammatory 
response has been growing until nowadays when it’s known that close to 
the early recognized inflammatory mediators, first biogenic amines and 
then prostaglandins, cytokines, chemokines, growth factors all 
participates in a coordinated network to orchestrate the inflammatory 
response. However, the ultimate purpose of inflammation is the 
restoration of tissue integrity (Medzhitov et al., 2008).  
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Figure 1. Cellular components of inflammation. 
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It is known that the natural outcome of the acute inflammatory program 
is the resolution and repair of tissue damage; failure of this program 
leads to chronic inflammation and loss of organ function. Thus together 
with pro-inflammatory mediators there are as many anti-inflammatory 
whose role is to dampen out inflammation.  
Resolution of inflammation may be considered an integral component of 
the program of acute inflammation. It is an active process regulated by 
natural immunosuppressive mechanisms, representing a “metabolic 
switch” to preserve host defense and tissue integrity. During the early 
stage of an inflammatory response a large number of leukocytes are 
recruited from circulation; at the end of the inflammatory process, these 
effectors cells will be cleared due to the loss of survival signals derived 
from the interactions with stromal cells, leading to apoptosis and 
subsequent phagocytosis of dead cells by monocytes – derived 
macrophages. Once phagocytosis is complete, macrophages exit the 
inflamed site by lymphatic drainage (Serhan and Seville, 2005; Serhan, 
2007). Another important aspect of resolution is that stromal cells that 
hosted the inflammatory event revert back to a no-inflammatory 
phenotype (Filer et al., 2006). In chronic inflammation, the resolution 
phase is prolonged and disordered, leading to the persistence of cell 
infiltrate that become rich in monocytes and T lymphocytes rather than 
neutrophils.  
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Thus, inflammation is also a “self-limiting” process; its turning into a 
chronic process can be understood as being the result of either the 
persistence of a stimulus, or of a deregulation of the endogenous anti-
inflammatory mechanisms that normally regulate its resolution (Serhan 
and Saville, 2005; Lawrence and Gilroy, 2007) (Figure 2). A novel anti-
inflammatory therapeutic approach would be to potentiate those 
mechanisms involved in the resolution phase. 
 
 Figure 2.Illustration of the cellular kinetics and sequential release of mediators during the 
evolution of the inflammatory response from onset to resolution. (A) Inflammation causes the 
immediate and sequential release of signalling factors to neutralize the injurious agent. (B) 
Failure of acute inflammation to resolve adequately could result in chronic inflammation (C) 
Thus, for the effective resolution of acute inflammation we need to curtail further influx of 
inflammatory leucocytes signal monocytes/macrophages to phagocytose and clear all these cells 
from the site of injury once the inflammatory stimulus posses no further threat. (Lawrence and 
Gilroy, 2007). 
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Linking inflammation and haemostasis 
 
Inflammation and haemostasis cannot be considered as two separate 
processes, since there are several connecting points making them part of 
unique, defensive host response. There is much evidence that 
inflammation triggers haemostatic imbalance. Experimental and clinical 
data demonstrate that inflammation is associated to an increased risk of 
cardiovascular events (Cicala and Cirino, 1998; Jurado and Ribero, 
1999; Cicala et al., 2007).  
During an inflammatory state, several cytokines by acting on the 
expression and synthesis of several proteins involved in coagulation and 
fibrinolysis are responsible for impairing the balance between pro- and 
anti- coagulant factors toward a pro-thrombotic state (Cicala and Cirino, 
1998). Indeed, proinflammatory cytokines (IL-1 and TNFα) increase 
tissue factor (TF) expression. TF is a 44000 molecular weight 
membrane-bound glycoprotein binding factor VIIa (Marmur et al., 
1996). The TF-VIIa complex activates factor X and factor IX, thereby 
initiating proteolytic cascades that result in thrombin formation and 
blood clotting (Fay et al., 2010). At the same time, cytokines, and in 
particular TNFα,  are mainly responsible for the downregulation of 
thrombomodulin (TM).  
TM is a high affinity receptor protein for thrombin and it is expressed on 
the endothelial surface. The thrombin-TM complex activates Protein C, 
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stimulating the fibrinolytic pathway. In the case of inflamed tissue, 
thrombin is not able to bind TM and therefore the fibrinolytic pathway is 
not activated. This phenomenon is due to the TM down-regulation 
caused by cytokine release into the inflamed site. In this way, it is clear 
that there is an alteration of the coagulative cascade that may lead to 
critical thrombus formation (Esmon, 2003) (Figure 3).  
Endothelium might be considered a surface interfacing inflammation and 
haemostasis. In particular, when the endothelium is under physiological 
conditions, the balance between its pro-and anti-thrombotic features is 
preserved; on the contrary, when the endothelium is damaged, it looses 
these properties and becomes an idoneous surface in which the first 
contact between inflammation and haemostasis takes place (Cicala and 
Cirino, 1998; Goran et al., 2006; Esmon et al., 2011).  
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Figure 3. The impact of coagulation on inflammation and the impact of 
inflammation on coagulation. Coagulation triggers platelet activation and 
leads to P selectin and CD40 ligand expression platelet surface. Inflammation 
in turn leads to tissue factor induction, leukocyte adhesion, thrombomodulin 
down regulation, and complement activation. Thus coagulation increases 
inflammation that in turn increases coagulation (Esmon et al., 2011). 
 
Another important aspect to be considered when the link between 
haemostasis and inflammation is examined is the contribution of 
platelets to both processes (Lindemann et al., 2001; Ruggeri, 2006). 
Platelets are considered like effective elements of the inflammatory 
system. Under physiological conditions, platelets circulate freely in the 
blood. On the contrary, when endothelium is damaged, platelets adhere 
to collagen fibres of the subendothelium, thereby becoming activated. 
Activated platelets express on their surface molecules driving platelet-
endothelium adhesion and platelet-leukocytes interaction (Figure 4).  
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Figure 4. Representation of thrombus development: A) vasoconstriction; B) 
primary hemostasis; C) secondary haemostasis; D) thrombus and anti-
thrombotic events. 
 
For example, P-selectin, translocated on platelet surface following 
activation, engages its receptor P-selectin glycoprotein -1 (PSGL-1) on 
polymorphonuclear (PMN) and monocytes; the interaction of platelets 
with leukocytes may result in local fibrin deposition through an 
increased TF expression in these cells (Palabrica et al., 1992; Celi et al., 
1994; Maugeri et al., 2006). 
The platelet receptor GPIbα, engaged on platelet surface following 
activation, binds to P-selectin and von Willebrand factor (vWF) 
externalized by endothelial cell granules following vascular damage 
(Nurden, 2011).  
Other adhesive proteins that have been described on platelets, important  
for cell-cell interaction, are CD40 and CD40L. On activated platelet 
A B 
C D 
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surface, CD40L by binding CD-40 (its counter-receptor on endothelial 
cells and monocyte/macrophages), promotes platelets-monocytes and 
platelets-endothelial cells interactions (Zarbock et al., 2007). The 
interaction between CD40L-CD40 promotes cell-cell adhesion but also 
up-regulates several functions in monocytes, such as chemokine and 
cytokine secretion, expression of tissue factor, upregulation of adhesive 
receptors and differentiation of monocytes into macrophages (Henn et 
al., 1998; Li et al., 2008; Cerletti et al., 2011). 
Another important molecule promoting platelet adhesion to endothelium 
and monocytes is C reactive protein (CRP). C reactive protein is an acute 
phase protein whose synthesis in the liver is under the control of 
cytokines. CRP has also been found in the walls of damaged vessels and 
into atherosclerotic plaques (Hirschfield and Pepys, 2003). 
CRP consists of five identical subunits of 206 aminoacids each; 
pentameric CRP can be dissociated in monomers either in vitro or in 
vivo. Pentameric and monomeric forms of CRP have been shown to 
possess different biological activity. Platelets express CRP receptors 
FcγRIII (CD16) and FcγRIIa (CD32) (Filep, 2009). It has been shown 
that pentameric CRP by binding to FcγRIIa on platelets inhibits 
platelets-neutrophils interactions (Khreiss et al., 2004). On the contrary, 
monomeric CRP, by binding to FcγRIII on platelets promotes platelet-
neutrophils interaction (Filep, 2009). Furthermore, activated platelets 
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convert pentameric CRP to monomeric. Thus, it is worth noting that 
CRP regulates platelet activation and, in turn, platelet activation 
regulates the conformational status and biological function of CRP. 
Thus, monomeric CRP, through platelet activation may lead to monocyte 
activation, thus representing an important mechanism linking 
platelet/monocyte activation and invasion of the vascular wall (Yaron et 
al., 2006; Danenberg et al., 2007; Fay, 2010).  
Furthermore, CRP inhibits also fibrinolytic pathway by inhibiting the 
release of tissue plasminogen activator (t-PA) and stimulating the release 
of plasminogen activator inhibitor-1 (PAI-1) from endothelial cells 
(Devaraj et al., 2003; Singh et al., 2005). In summary, CRP, that since 
long time has been considered a marker of cardiovascular risk during 
inflammation, is now known to play an active role in linking 
inflammation and thrombosis by affecting the function of blood platelets, 
coagulation cascade and the fibrinolytic pathway.  
Adenine nucleotides (ATP and ADP) are platelet activators; conversely, 
adenosine, the final product of the nucleotide hydrolysis, is a vasodilator 
and inhibitor of platelet aggregation (Burnstock, 1990). In an 
inflammatory environment, ADP released from activated platelets 
contributes to stimulate other platelets. CD39 is an ecto-nucleoside 
triphosphate diphosphoydrolase (E-NTPDase), ubiquitously expressed 
on cell surface, metabolizing ATP to ADP and to AMP, thus reducing 
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ADP concentration at the site of injury. Hence, CD39 has been 
considered a key modulator of thrombus formation. In an inflammatory 
environment the loss of CD39 activity from activated endothelium 
sustains platelet aggregation and thrombogenesis (Atkinson et al., 2006). 
On the other hand, within a damaged tissue  the increased expression of 
CD39 on inflammatory cells, working in tandem with CD73 (catalyzing 
the conversion of AMP to adenosine) might cause inhibition of  platelet 
activation by increasing extracellular adenosine levels (Johnston-Cox et 
al., 2010).  
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ADENOSINE  
 
Prolonged and inappropriate inflammation due to the persistence of 
cytotoxic proinflammatory molecules may cause destruction of normal 
bystander cells. Thus, prolonged and inappropriate inflammation must be 
regulated by natural immunosuppressive mechanisms, representing a 
“metabolic switch” to preserve host defense and tissue integrity. 
Adenosine and its receptors are possible candidates involved in the 
natural down-regulation of inflammation (Linden, 2006; Fredholm, 
2007) 
Adenosine is a nucleoside always present both within and outside cells in 
nanomolar concentration (10 – 100 nM) under physiological conditions, 
deriving by the breakdown of intra – or –extra cellular adenine 
nucleotides. Physiologically, adenosine concentration is constant and 
finely regulated by an equilibrium between the extracellular release and 
the cellular re –uptake and its conversion to inosine. Two enzymes 
regulate this equilibrium: adenosine deaminase (ADA) and adenosine 
kinase. ADA is mainly a cytosolic enzyme but can also appears on the 
cell surface of several immune and non immune cells (ectoADA); ADA 
catalyzes the deamination of adenosine to inosine. Adenosine kinase is 
an intracellular enzyme catalyzing the adenosine phosphorylation to 
AMP (Bours et al., 2006).  
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Following trauma or cellular stress, such as during hypoxia, ischemia or 
inflammation, extracellular adenosine levels increase rapidly following 
ATP degradation (Fredholm, 2007).  
Two ecto – enzymes working in concert, the nucleoside triphosphate 
diphosphohydrolases, ecto-apyrase (CD39), and an ecto- 5’- nucleotidase 
(CD73), are involved in the adenine nucleotides (ATP and AMP 
respectively) breakdown in adenosine; they are located on cell surface 
but may be found as soluble forms in the interstitial medium and in body 
fluids (Schetinger et al., 2007) (Figure 5).  
 
 
Figure 5. Metabolism of adenosine 
 
Extracellular adenosine accumulation represents an early endogenous 
signal controlling inflammation and immune responses. Adenosine 
protective effects fall in four main mechanisms: it is protective against 
ischemic damage by cell conditioning; it increases the ratio of oxygen 
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supply to demand; it promotes angiogenesis and it has antinflammatory 
effects. (Lankford et al., 2006; Fredholm, 2007) (Figure 6). 
 
Figure 6.The inflammatory response to infection or tissue damage depends on 
the coordination of adenine nucleotide metabolism and signaling among many 
cell types via purinergic receptors that recognize ATP, ADP, or adenosine. A 
neutrophil migrating toward a chemotactic stimulus (fMLP) releases ATP 
from its leading edge. ATP is dephosphorylated by ectoenzymes (CD39 and 
CD73) to ADP and adenosine. Gradients of ATP and adenosine initiate and 
accelerate directional chemotaxis via P2Y2 and A3 adenosine receptors, 
respectively, on neutrophils. Other adenosine receptors (A2A and A2B) inhibit 
neutrophil chemotaxis and adhesion to endothelial cells, as well as platelet 
aggregation. 
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Adenosine Receptors 
 
Adenosine effects are mediated through the interaction with four G-
protein coupled receptors, indicated as A1, A2A, A2B, A3, (Figure 7), 
belonging to the family of purinergic P1 receptors. They are widely 
expressed on a variety of immune and non immune cells (Table I). 
Although they bind the same agonist, they differ in several aspects, 
including their affinity binding for the agonist; their expression profile in 
different cell types; the identity of the G – proteins to which they are 
coupled and their sensitivity to receptor phosphorylation. All these 
factors combined determine the extent, the duration and the outcome of 
cellular exposure to adenosine and, in the end, dictate the nature of the 
response to adenosine tissue accumulation (Polosa 2002; Hasko and 
Cronstein, 2004).  
 
 
Table I: Pharmacological classification and anatomical distribution of adenosine-
receptor subtypes. 
 
 
 
 
 
 
 
Receptor 
subtype 
Agonist Antagonists Distribution 
A1 CHA>NECA>CGS21680 DPCPX>XAC>CGS15943
>SPT 
Heart, adipocytes, respiratory smooth 
muscle, neutrophils, kidney, hippocampus 
cortex 
A2A CGS21680~NECA>>CHA ZM241385~SCH58261~C
GS15943>XAC>DPCPX 
Platelets, neutrophils, vasculature, 
pancreas, mast cells, striatum 
A2B NECA>CHA>>CGS21680 XAC>CGS15943>DPCPX Vascular, intestinal and respiratory 
smooth muscle, chromaffin tissue, mast 
cells, brain 
A3 2-CI-IB-
MECA>APNEA>NECA~ 
CGS21680 
MRS1220~IABOPX>L268
605>>XAC>DPCX 
Testis, kidney, lung, must cells, 
eosinophils, neutrophils, heart, cortex, 
striatum 
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A1 adenosine receptor (A1R), a high affinity receptor, is coupled to a Gi and Go 
proteins, its activation results in adenylyl cyclase activity inhibition and 
increased activity of phospholipase C (PLC) through Gβγ subunits. Into the 
cardiac muscle, A1R can activate a potassium channel, leading to an increased 
K+ efflux from the cell. This adenosine receptor subtype is found in adipose 
tissue, heart muscle, central nervous system, airways and inflammatory cells 
such as neutrophils. 
A2Aadenosine receptor (A2AR), a high affinity receptor, is coupled to a Gs 
protein, its activation results in the increase of adenylyl cyclase activity. 
A2A receptors are expressed in the central nervous system, vascular 
smooth muscle, endothelium and on neutrophils, platelets, mast cells and 
T cells. 
A2B adenosine receptor (A2BR), a low affinity receptor, is coupled to both 
Gs and Gq, its activation may lead to increased adenylyl cyclase activity 
(Gs) or to phospholipase C (PLC) activation (Gq) resulting in calcium 
mobilization. It has been identified widely including in the brain, human 
bronchial epithelium, endothelial cells, muscle cells, neurons, glial cells, 
fibroblasts and mast cells.  
A3 adenosine receptor (A3R), a low affinity receptor, is coupled to a Gi 
and its activation results in adenylyl cyclase activity inhibition but it can 
also stimulate PLC, leading to increased calcium concentration. The A3 
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receptor is widely distributed, being found in the kidney, testis, lung, 
mast cells, eosinophils, neutrophils, the heart and brain cortex.  
Adenosine receptors are expressed on all cell types involved in 
orchestrating an inflammatory/immune response, including 
monocytes/macrophages, dendritic cells, mast cells, neutrophils, 
eosinophils, platelets, fibroblasts, epithelial cells, endothelial cells. 
Through the interactions with its receptors adenosine may be beneficial 
or detrimental to tissues (Polosa, 2002; Linden, 2001; Burnstock, 2006). 
 
Figure 7. Adenosine receptors
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Adenosine and inflammation  
 
As described above, inflammatory tissue injury is accompanied by 
increased levels of extracellular adenosine; the most important factor 
causing adenosine accumulation is hypoxia in inflamed tissue.   
Recently, considerable evidence has been accumulated on adenosine 
involvement in inflammation through activation of its receptors. The 
interest on the role of adenosine in inflammation has been growing also 
following the finding that some antinflammatory drugs, nimesulide, 
salycilates, and methotrexate exert their effects through adenosine 
signaling (Capecchi et al., 1993; Cronstein,et al., 1993; 1999; Cronstein, 
1994; Amann and Peskar, 2002; Bernardi et al., 2007).  
On inflammatory cells, adenosine may have opposite effect, being 
protective or harmful, depending on receptor subtype activation. This 
discrepancy between pro - and anti- inflammatory adenosine effects 
might also been attributed to the different receptor distribution in 
different tissue and/or to an alteration of tissue receptor expression under 
pathological conditions (Zimmermann, 2000; Bours et al., 2006).   
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Adenosine A2A receptor and inflammation  
 
There is in vitro and in vivo evidence that adenosine signalling through 
A2A receptor plays the major role in controlling inflammation and 
immune response.  
In vitro studies have demonstrated that A2A activation on neutrophils 
inhibits oxidative burst and chemokine production in response to several 
stimuli (Cronstein et al., 1986; 1988; Barnes et al., 1995; McColl et al., 
2006) and on human monocytes the release of proinflammatory 
cytokines. Trough A2A receptor on lymphocytes, adenosine inhibits 
activation and expansion. The majority of A2A receptor inhibitory effects 
on immune and inflammatory processes have been propose to occur via 
cAMP/PKA activation. (Huang et al., 1997; Haskò and Cronstein, 2004; 
Haskò et al., 2007). 
Studies performed in vivo have demonstrated that administration of 
selective A2A agonists inhibits inflammation in models of ischemia 
reperfusion injury of various organs; A2A inhibits also lung inflammation 
caused by pro- inflammatory stimuli (Palmer and Trevethick, 2008).  
Furthermore, in vivo studies have demonstrated that administration of the 
A2A agonist, CGS21680 to ovalbumin (OVA) sensitized mice reduces 
cell influx to the airways (Bonneau et al., 2006). The protective effect of 
A2A receptor has also been demonstrated in a murine model of LPS-
induced acute respiratory distress syndrome (Thiel et al., 2005). 
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Furthermore, it has been demonstrated that A2A activation also protects 
from stress – induced gastric lesion in the rat that are dependent upon 
neutrophil infiltration (Odashima et al., 2005). It has been shown that 
A2A receptor activation on neutrophils increases COX2 expression and 
the following production of PGE2, a prostanoid with antinflammatory 
properties (Cadiaux et al., 2005). More recently it has been demonstrated 
a beneficial role for A2A agonist, CGS21689, also in a model of chronic 
inflammation, as collagen induced arthritis in mice (Mazzon et al., 
2011). 
A2A adenosine receptor has also been shown to play a role in matrix 
deposition and wound healing in a damaged tissue, contributing to either 
fibrotic disorders and repairing processes (Montesinos et al., 1997; Chan 
et al., 2006A; Cronstein, 2006) (Figure 8) 
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Figure 8. During inflammation, the formation of a blood clot re-establishes 
hemostasis and provides a provisional matrix for cell migration. Cytokines 
play an important role in the evolution of granulation tissue through 
recruitment of inflammatory leukocytes and stimulation of fibroblasts and 
epithelial cells 
 
 
By performing experiments in A2A deficient mice it has been 
demonstrated that A2A receptor signaling represent an endogenous 
antinflammatory mechanism; indeed, mice deficient in A2A receptor 
display an exaggerated inflammatory response in models of hepatitis and 
sepsis  (Ohta et al., 2001; Chan et al., 2006 B). Furthermore, mice 
lacking A2A receptor have shown exaggerated lung inflammation and cell 
infiltration following sensitization (Nadeem et al., 2007).  
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A2A receptor expression on immune and endothelial cells is up-regulated 
by inflammatory cytokines (IL-1β, TNFα) (Khoa et al., 2004; Nguyen et 
al., 2003). All these data support the hypothesis that in an inflammatory 
environment signaling through A2A receptor functions to switch off the 
inflammatory process. 
 
Ectonucleotidases 
 
Ectonucleotidases are enzymes that hydrolyze extracellular nucleotides 
to their respective nucleosides. There are four major families of 
ectonucleotidases, namely E-NTPDases (ATP to ADP and ADP to 
AMP), alkaline phosphatases (ATP to ADP to AMP to Adenosine), E-
NPPtype pyrophosphatase/phosphodiesterase (ATP to AMP) and Ecto-
5’-nucleotidase (AMP to adenosine). The distribution of 
ectonucleotidases is as ubiquitous as that of nucleotide receptors 
(Schetinger et al, 2007). 
Although there is much work confirming adenosine protective role in 
inflammation, it is not yet clear the mechanism at the basis of adenosine 
antinflammatory effect neither how steps involved in extracellular 
adenosine accumulation are regulated during inflammation. 
Two ectonucleotidases (CD39 and CD73) play a key role in extracellular 
adenosine accumulation. NTPDase 1 (CD 39), ecto-apyrase, degrades 
equally well ATP and ADP. Ecto 5’- nucleotidase (CD73) degrades 
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AMP in adenosine. The central function of these enzymes is to increase 
extracellular production of adenosine.  
To date, it is has been shown that stimuli causing adenosine 
accumulation cause also an increased expression of these enzymes on 
cells (Robson et al., 2006; Schetinger et al., 2007).  
There is evidence that inflammatory stimuli increase CD39 and CD73 
expression and/or activity on cells involved in the inflammatory/immune 
responses, such as neutrophils, monocytes, lymphocytes. It has been 
demonstrated that following hypoxia activated neutrophils release ATP; 
at the same time hypoxia induces an increased expression of CD39 and 
CD73 on vascular endothelium causing a rapid formation of adenosine 
deriving from ATP breakdown. Adenosine, in turn, via A2A activation 
inhibits neutrophil function; indeed, knock out mice for these enzymes 
show increased neutrophil accumulation following hypoxia (Eltzschig et 
al., 2004). Thus, the increased adenosine levels provide a negative 
feedback signal that counteract neutrophil activation; high levels of 
extracellular adenosine, following tissue damage, are conserved by the 
increased CD39 and CD73 expression (Eltzschig et al., 2004; Bours et 
al., 2006). In vivo, by performing experiments in CD39 null mice it has 
been shown that CD39 is required for optimal stimulation of hapten 
reactive T-cell (Mizumoto et al., 2002).  
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Both CD39, ecto– apyrase, and Cd73 on endothelial cells play a 
protective role against vascular injury. In a model of hypoxia in vivo, in 
knock out mice for CD73 it has been shown that this enzyme through the 
generation of extracellular adenosine plays a crucial role for vascular 
leakage (Thompson et al., 2004). 
In mice airways, CD39 and CD73 have shown to be an innate protective 
pathway from damage caused by mechanical ventilation (Eckle; 2007). 
Both enzyme are also over expressed in airways of mice following LPS-
induced lung injury and play a role in attenuating polymorphonuclear 
trafficking (Reutershan et al., 2009).  
As described above, CD39 plays a critical role in the control of vascular 
thrombosis; it has been shown that following endothelial cell activation 
the ATPDase is lost and this might contribute to vascular damage 
(Atkinson et al., 2006). Nonetheless, transgenic mice overexpressing 
CD39 are protected from myocardial ischemia injury (Cai et al., 2011; 
Deaglio et al., 2011).  
Thus, these enzymes might represent a key step of a natural metabolic 
switch whose final product is represented by adenosine. A better 
knowledge on the role of these enzymes in inflammation would help to 
clarify the physiopathology of inflammation and to identify therapeutic 
target that activate endogenous protective mechanisms.  
  32 
INTERLEUKIN 17 
 
Interleukin-17: family overview 
 
IL-17A, a 153 amino acid polypeptide, is the oldest described member of 
IL-17 family. It represents the prototypic member of a family of 
cytokines that also includes IL-17B, IL-17C, IL-17D and IL-17F (Table 
II and Figure 9). IL-17E was independently identified; now it has been 
renamed IL-25 and it is no longer considered as a member of IL-17 
family, it has been shown to have anti-inflammatory properties by 
inducing Th2 responses (Kolls and Linden, 2004). IL-17 (synonymous of 
IL-17A) is a homodymeric glycoprotein of 155 aminoacids and a 
molecular weight (MW) of 35 kDa.  
All members of this cytokine family, except IL-17B, exert their 
biological effects as dimers, by binding to IL-17 receptors that are 
ubiquitously expressed.  
IL-17A and IL-17F are the best characterized members of this cytokine 
family. Both are homodimers, but recent findings show that mouse and 
human CD4+ cells can produce heterodimer forms of IL-17A-IL17F 
(Chang et al., 2007).  
IL-17 is mainly produced by a subset of T helper cells (CD4+ cells) 
termed Th17, phenotypically and functionally distinct from Th1, Th2 
and T regulatory cells (T reg).  
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In mice, the presence of two cytokines, transforming growth factor β 
(TGFβ) and IL-6, is responsible for naïve Th cells polarization towards a 
Th-17 subtype; both cytokines cause upregulation of  IL-23 receptor 
expression on T cells and, in turn, IL-23, together with IL-12, stimulates 
IL-17 production in Th17 cells. Humans Th17 display similarities and 
differences in their differentiation, with mouse Th-17 cells: IL-1β, IL-23 
and IL-6 seems to drive differentiation of naïve Th cells towards Th-17, 
however is still unclear the role of TGFβ. It is worth noting that besides 
Th-17, other cell types can produce IL-17 such as natural killer T cells 
and neutrophils (Aggarwal et al., 2002).   
 
Table II: The human IL-17 cytokine family. 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-17 family 
member 
Molecular 
weight (kDa) 
Receptor Source Proposed pathogenic role 
IL-17 35 IL-17RA+C TH-17 cells, CD8cells, T 
cells, iNKT cells, 
granulocytes(?), 
macrophages (?) 
Induction of neutrophil-mobilizing 
mediators, induction of 
antimicrobial cytokines, 
accumulation of neutrophils, 
stimulation of osteoclastogenesis 
IL-17B 41 IL-17 RB Not determined Not determined 
IL-17C 40 ? Not determined Not determined 
IL-17D 52 ? Not determined Not determined 
IL-17F 44 ? Th-17 cells Induction of neutrophil-mobilizing 
mediators, accumulation of 
neutrophils 
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Figure 9. Interleukin-17 family 
 
Interleukin-17: receptor family 
 
The IL-17R family consists of  five receptor subunits, from IL-17RA to 
IL-17RE (Aggarwal, et al., 2002). IL-17RA is a type I transmembrane 
protein consisting of  an extracellular domain (293 AA), a 
transmembrane domain (21 AA) and a cytoplasmic domain (21AA). IL-
17 RA is expressed in a variety of cells in humans and mice, such as 
epithelial cells, fibroblasts, B and T lymphocytes, neutrophils, bone 
marrow cells (Linden et al., 2005; Dragon et al., 2008). IL-17A 
stimulates a receptor complex formed of IL-17RA and IL-17RC; the 
latter shows similarities to IL-17RA while the functional characteristics 
of the other receptors  are still unclear (Ivanov and Lindén, 2008).  
Following activation of the IL-17R complex, IL-17A signalling involves 
at least two downstream pathways; the first involves the adaptor protein 
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nuclear factor-kB activator (Act-1) that forms a complex with the SEFIR 
domain (a cytoplasmic protein segment present in all members of IL-
17R family); subsequently, intracellular signalling molecules, such as 
tumour necrosis factor- receptor associated factor (TRAF 6 and TRAF3) 
and transforming growth factor activated kinase 1 (TAK1) are activated 
and, in turn, mediate the activation of transcription factors. The second 
pathway described is Act-1-independent and involves activation of Janus 
kinase-1(JAK1) and phosphatidylinositol 3-kinase (PI3K), followed by 
subsequent inactivation of glycogen synthase kinase (GSK)-3β and gene 
activation (Ivanov and Linden 2008) (Figure 10).  
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Figure 10. Intracellular IL-17 signaling. (a) Act-1 dependent: after ligand 
activation of the Il-17 receptor R complex (i.e. IL-17 RA and IL-17 RC), the 
adaptor protein nuclear factor κB activator 1 (Act-1) forms a complex with the 
similar expression to fibroblast grow factor (FGF) genes and IL-17 receptor 
(SEFIR)domain of IL-17 R complex. Subsequently, intracellular signal 
molecules (e.g. TRAF3, TRAF6, and TAK1) are activated loading to the 
involvement of transcription factors such as NF-κB. As consequence secretion 
of neutrophil-mobilizing is induced. b) Act-1 independent: it involves Janus 
kinase (JAK)1 and phosphatidylinositol3-kinase (Pl3K) followed by 
subsequent inactivation of glycogen synthase kinase (GSK)-3β, gene 
activation and cytokine secretion.Interleukin-17A and inflammation. 
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Interleukin 17 and inflammation 
IL-17A has an unique role in the context of inflammatory response 
(Kolls and Linden, 2004). This cytokine is produced mainly by T cells 
rather than by macrophages or other cells of the innate immune system 
and thus it is believed to play important role in the inflammatory events 
triggered by the adaptive or memory immune system (Dong,  2008). On 
the basis of these hypothesis, in vitro and in vivo studies have shown that 
IL-17A cooperates either additively or sinergically with various 
cytokines or mediators inducing inflammation (Katz et al., 2001). 
Indeed, recently, by using a murine model of inflammation, it has been 
shown that IL-17A is not a classical proinflammatory cytokine and it is 
no able to initiate per se an inflammatory reaction. On the contrary, this 
cytokine is able to further amplify biochemical and cellular events 
characteristic of the early stages of the inflammatory reaction, when it  is 
injected in pre-inflamed tissue (Maione et al., 2009).  
Another important aspect of Th-17 cells is their capacity to produce not 
only IL-17 but also other cytokines, such as IL-2 and IL-22, IL-26, 
CCL20. Th17 derived cytokines induce the production of IL-6, TNFα, 
CXCL1, CXCL2, CXCL8, CCL2 and metalloproteinases, MMP-3, 
MMP-6 and MMP-13, from various tissues and cell types (Strezpa et al., 
2011).  
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Important differences, as well as many similarities, emerge when the 
biology of Th17 cells in the mouse is compared with corresponding 
phenomena in humans (Aggarwal et al., 2002). However, in this context, 
it is very important to underline that  IL -17A has in vivo as well as in 
vitro inflammatory properties. One of the main cellular target of this 
molecule are the neutrophil-cells, in fact it is known that IL-17A 
stimulates the production of chemokines, such as IL-8 (CXCL8) and 
granulocyte-chemotactic protein - 2 (GCP-2), growth factors, such as 
CSF and GM-CSF, the neutrophils activating cytokine, IL-6,  from 
epithelial cells, smooth muscle cells and fibroblasts. Furthermore, IL-
17A increases local sign of neutrophil activation, such as the activity of 
myeloperoxidase (MPO), elastase and matrix metalloproteinase (MMP-
9) (Fossiez et al., 1996; Hoshino et al., 2000; Jones et al., 2002).  
As reported by Fouser and co-workers, IL-17A sustains, induces and 
amplifies the inflammatory  response on a pre-existing tissue injury 
(Fouser et al., 2008).  
On the basis of the considerations reported here, it is clear that Th-17 
cells, through IL-17, drive the inflammatory cascade by stimulating cells 
to release a large number of  inflammatory mediators and growth factors 
that have important effects on neuroendocrine and metabolic functions 
and on the maintenance of tissue homeostasis in general.  
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Interleukin-17 and  autoimmune diseases 
Growing evidence, gathered over the last few years, indicate that IL-17A 
might play a key role in the development of autoimmune diseases. IL-17 
is an important factor directing disease progression in multiple sclerosis 
(MS). Multiple sclerosis is a central nervous system (CNS) disease 
associated with destruction of myelin sheets, leading to impaired nerve 
signal transduction. Similar to other proinflammatory cytokines, the 
concentration of IL-17A is increased in CNS lesions of MS patients and 
correlates with neutrophil infiltration of the CNS (Lock et al., 2002).  
The role of IL-17A in the rheumatoid arthritis (RA) is more complex. 
The  pathological role of IL-17A in arthritic joints involves the 
stimulation of MMP, vascular endothelial growth factor (VEGF) and 
proiflammatory cytokine production and increased recruitment of T 
lymphocytes and innate immune cells (Kotake et al., 1999). However, 
these processes are not attenuated when arthritis is induced in IL-17 -/- 
mice; this evidence suggests that other factors involved have a 
substitutive role and demonstrates that the role of IL-17 is still unclear 
(Doodes et al., 2008). Nonetheless, in experiments performed by using a 
murine model of collagen-induced arthritis it has been demonstrated a 
beneficial effect of the animal treatment with  an anti IL-17 antibody 
(Nakae et al., 2003).  
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In patients affected by psoriasis and chronic skin disease, high levels of 
IL-17 have been found in skin lesions. Particularly, these types of 
diseases are characterized by a hyperproliferation of keratinocytes and 
production of proinflammatory molecules increasing angiogenesis and T 
cell infiltration. In these cases, it has been shown a possible synergism 
between IL-17 and other Th17 associated inflammatory cytokines (IL-23 
and IL-22) with IFN-gamma in promoting characteristic pathologic 
changes (Teunissen et al., 1998; Zheng et al., 2007).  
Furthermore, IL-17 and IL-23 have also been associated to Crohn’s 
disease and colitis ulcerosa; however, the role of  IL-17 in intestinal 
inflammation is still controversial, indeed this cytokine has been shown 
to be either protective or proinflammatory  in two different models of 
murine colitis (Zhang et al., 2006; O’Connor et al., 2009). 
Allergic asthma represents another disease in which IL-17 plays a crucial 
role. Allergic asthma is characterized by elevated IgE serum levels, 
chronic airway inflammation with intense cell accumulation, mucus 
hyperproduction and airway hyperresponsiveness to a large variety of 
stimuli (Souwer et al., 2010. Asthma induces many irreversible changes 
in airway tissues. Accumulating evidence indicates that in 
bronchoalveolar lavage (BAL) fluid of patients with severe asthma there 
are elevated levels of IL-17, in comparison to moderate asthmatic 
patients and to control subjects; a role for IL-17 in inducing  neutrophil 
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accumulation into asthmatic airways have been suggested. (Molet et al., 
2001).  
In addition to neutrophil recruitment, IL-17 may also stimulate 
neutrophil activity since it stimulates the release of neutrophil-activating 
cytokines, IL-6 and IL-8, from bronchial epithelial cells and fibroblasts; 
furthermore, it may also play a role in causing structural changes in the 
airways, since causes the production of profibrotic cytokines, IL-6 and 
IL-11, from fibroblasts (Fossiez  et al., 1996; Molet et al., 2001). 
Recently, by performing experiment on an in vivo model of murine 
asthma, it has been shown that the increased expression of heparin-
binding epidermal growth factor (HB-EGF), induced by IL-17, might be 
responsible of mucus overproduction and airway smooth muscle cell 
proliferation in chronic asthma (Wang et al., 2010). Targeting IL-17 may 
be useful for the treatment of asthma. It has been shown that 
neutralization of IL-17 with monoclonal antibodies reduces neutrophil 
accumulation in BALF (Helling et al., 2003). 
Il-17 plays also a role in chronic obstructive pulmonary disease (COPD) 
(Figure 11); indeed by releasing chemokines (CXCL1, CXCL6 and 
CXCL8) and granulocyte survival factors (GM-CSF and G-CSF) from 
airway epithelial cells it would increase neutrophil chemotaxis and 
prevent apoptosis (Jones et al., 2002; Vanaudenaerde et al., 2003; 
Rahman et al., 2005; Traves and Donnelly, 2008).  
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Figure 11. Interleukin-17 and chronic obstructive pulmonary disease (COPD). 
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IL-17 and cardiovascular risk 
As described above, there is much evidence, either experimental or 
clinical, that thrombosis and atherosclerosis might be closely associated 
to an inflammatory reaction, (Jurado and Ribeiro; 1999, Esmon; 2003, 
Strukova; 2006). It is known that inflammation initiates clotting, 
decreases the activity of natural anticoagulant mechanisms and impairs 
the fibrinolytic system. Nonetheless, proteases involved in coagulation 
system contribute to inflammation not only by promoting fibrin 
formation at site of injury, but also by stimulating several cell functions 
(Cicala and Cirino,1998; Esmon, 2008). On the other hand, pro-
inflammatory molecules are actively involved in the activation and 
migration of  leukocytes to sites of vascular injury and inflammation, 
and may contribute to the release by activated cells of prothrombotic 
factors, which in turn may activate platelets and other cell types (Ruggeri 
et al.; 2007, Lambert et al.; 2007). 
In agreement with this, there is much evidence that patients suffering 
from autoimmune diseases have an elevated risk of thrombosis (Gisondi 
et Girolomoni, 2009; Mameli et al., 2009). As described above, multiple 
factors may be implicated; it is known that circulating cytokines and 
recruited inflammatory cells cause endothelial dysfunction and 
haemostatic disorders leading toward a prothrombotic state (Cicala and 
Cirino, 1997; Nurden, 2011). Furthermore, it has also been hypothesized 
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that in rheumatic diseases atherosclerotic lesions might be more prone to 
the rupture leading to acute cardiovascular events (Frostegard et al., 
2011).  
Evidence that increased IL-17 levels are associated with coronary artery 
disease (Eid et al., 2009; Wang et al., 2011) and atherosclerosis (Cheng 
et al., 2008) has suggested that this cytokine may play a role at the 
interface between inflammatory immune disorders and cardiovascular 
risk. In vitro experimental data show that IL-17 stimulates C-reactive 
protein expression in human hepatocyte and coronary artery smooth 
muscle cells (Patel et al., 2007). It is known that CRP is not only a 
marker of cardiovascular risk but, as described above, directly participate 
to endothelial dysfunction and may stimulate platelet aggregation and  
platelet/leukocytes interaction (Fay, 2010; Hirschfield and Pepys, 2003).  
Recently, by performing experiments in vitro,  it has been shown that IL-
17A favours the aggregation of murine and human platelets in response 
to ADP. The effect of IL-17A on platelets, in vitro, is paralleled by an 
increased expression of P-selectin on platelet surface (Maione et al., 
2011). It is well-established that platelet adhesion is mediated via 
glycoprotein GPIb receptors through interaction with the von Willebrand 
factor and that further physiologic activation of platelets via intracellular 
signalling pathways leads not only to an increased expression of the 
GPIIb/IIIa receptor complex, but also to a conformational change and 
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exposure of the fibrinogen binding site. Subsequent fibrinogen bridging 
allows firm attachment of adjacent platelets (Clemetson et al., 1995). 
This process is a prerequisite for platelet aggregation and thrombus 
formation. Similarly, the increased platelet expression of CD62P is 
predictive for an elevated risk of circulating platelet-leukocyte 
aggregates that are typically considered predictive of thrombus 
formation (Wohner et al., 2008) and observed in patients with acute 
myocardial infarction (Furman et al., 2001) as well as in patients 
suffering of autoimmune diseases (Joseph et al., 2001; Hu et al.,2004; 
Irving et al., 2004). 
 
  
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL SECTION 
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ADENOSINE AND INFLAMMATION  
 
MATERIALS AND METHODS 
Animals 
All experiments were performed on male Wistar rats (Charles River; 
120-150g). Rats were slightly anaesthetized with enflurane. 100 µl of 
carrageenan (1 % w/v in saline) were injected in the rat hind paw to 
obtain an oedema. Then, oedema was measured by the means 
hydroplethismometer at time zero and each hour for the following 6 
hours.  
Drug treatments 
To investigate on the role of adenosine A2A receptor activation on 
carrageenan oedema development, animals were divided in 5 groups and 
treated, just before oedema induction,   with the intraperitoneal  injection 
of: A2A agonist,  CGS 21680 (0.02, 0.2 and 2 mg / kg); A2A antagonist,  
ZM 241385 (3 mg/kg ); CGS 21680 (2 mg/kg) plus ZM 241385 (3 mg 
/kg ) and the respective vehicles. At different times following oedema 
induction, the paws were excised, cut, frozen in liquid nitrogen or fixed 
in buffered formalin 10 % (v/v) and stored.  
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Myeloperoxidase (MPO) assay  
Myeloperoxidase activity was measured from animals treated with the 
selective adenosine A2A receptor agonist, CGS 21680 (0.02, 0.2 and 2 
mg/kg ip.) or with the vehicle (DMSO; 0.5 ml/kg ip.), inflamed paws 
were excised after 3 hours from oedema induction and the soft tissue was 
removed, frozen in liquid nitrogen and stored. Tissue samples were then 
defrosted, weighed and homogenized in a solution containing 0.5 % 
(w/v) hexadecyltrimethylammonium bromide dissolved in 10 mM 
potassium phosphate buffer (pH 7) and centrifuged at 12000 rpm for 30 
minutes at 4°C; an aliquot of the supernatant was then allowed to react 
with 0.167 mg/ml o-dianisidine dihydrocloride and 0.001 % H2O2. The 
rate of change in absorbance was measured spectrophotometrically at 
650 nm; MPO activity was defined as the quantity of enzyme degrading 
1 µmol/min of peroxide at 37°C and was expressed in milliunits per g of 
wet tissue (mU/g tissue). 
Western blot analysis  
Tissue samples were defrosted, weighed and homogenized with a 
Polytron. In order to extrapolate proteins, 1 ml of  buffer (β-
glycerophosphate 50 mM; sodium ortovanadate 100µM; MgCl2 2mM; 
EGTA 1mM; DTT 1 mM; PMSF 1mM; Aprotinin 10µg/ml; leupeptin 
10µg/ml) was added to 100 mg of tissue samples. The homogenates were 
centrifuged at 2500 rpm for 10 minutes at 4°C. The pellets were then 
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centrifuged  at 12000 rpm. for 30 minutes at 4°C in order to measure the 
protein content via Bradford assay. Proteins were separated by Sodium 
Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
(12 %); 40 µg of protein were applied on the gel and electrophorezed at 
90 mV. for 1.5 hours. The protein samples were then electro-blotted at 
250 mA for 1.30 h using nitrocellulose membrane. Afterwards, 
nitrocellulose membrane was blocked using a blocking solution 
containing 5% (w/v) non-fat dry milk, 0.1% (w/v) Bovine Serum 
Albumin (BSA) and 0.1% (v/v) Tween 20 in phosphate buffer solution 
(PBS), for 2h at room temperature. Then, it was incubated overnight  at 
4° C on a shaker with anti A2A(R-18, Santa Cruz)  goat antibody 
(dilution 1:500). The nitrocellulose membrane was washed five times for 
25 minutes and then incubated with the secondary antibody anti-goat 
IgG (dilution 1: 5000) conjugated with horseradish peroxidase for 2h at 
room temperature. After five washes, the proteins bands were detected 
using the enhanced chemiluminescence (ECL) method and analyze with 
Image Quant 400 GE Healthcare software (GE Healtchcare, Italy) as 
described by the manufacturer.  
Immunohistochemical localization of A2A  
Tissue samples removed, as described above, were prepared from 
paraffin embedded tissues. After deparaffinization and rehydration of 
tissue section (thickness 7 µm), antigen retrieval was performed for  30 
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minutes at 100°C with 0.01 M citrate buffer (pH 6.0). To block no-
specific binding, slides were incubated for 10 min at room temperature 
with the protein block serum free solution (Dako). Endogenous biotin or 
avidin binding sites were blocked by sequential incubation for 15 min 
with avidin and biotin. Then the sections were incubated overnight with 
primary goat anti-A2A antibody (Santa Cruz) (dilution 1:250) in PBS and 
BSA 1%, overnight at 4 °C,  or with control solutions including buffer 
alone or no-specific purified rabbit IgG.  
After washing, endogenous peroxidase was quenched with 0.3 % (v/v) 
H2O2 in 60 % (v/v) methanol for 10 min. Specific labeling was detected 
with a biotin-conjugated universal secondary antibody (Universal 
DakoCytomation LSAB  Kit) for 30 min at room temperature followed 
by incubation with streptavidin-HRP. After washing, slides were 
incubated with Diaminobenzidine (DAB). The counterstaining was 
performed with hematoxylin. Negative staining control experiments 
were performed according to the protocol described above, with 
omission of the primary antibody.  
 
Picro Sirius red staining for collagen detection 
Picro Sirius stain was applied to visualize collagen content. Briefly, the 
paraffin sections were de-waxed and rehydrate. The sections were 
stained with Mayer’s haematoxylin to visualize the nuclei and than 
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incubated in the Pico Sirius red solution for one hour. The sections were 
washed with acidified water, dehydrated and cleared in xylene before 
mounted in a resinous medium. 
Statistical analysis 
All results were expressed as mean ± error standard and analyzed by one 
way ANOVA followed by Bonferroni’s test for multiple comparisons or 
Dunnett’s test. A value of P < 0.05 was taken as statically significant. 
 
 RESULTS 
Effect of  CGS 21680 treatment on carrageenan – induced oedema 
Injection of carrageenan in the rat hind paw caused an oedema peaking 
between 3 and 4 hours. Treatment with CGS 21680 inhibited oedema 
development in a dose – related manner, and this effect was reverted by 
co-administration with the A2A antagonist, ZM 241385. On the contrary, 
ZM 241385 alone did not modify oedema (Figure 12-13) 
 
 
Figure 12.  Effect of the selective adenosine A2A receptor agonist CGS 21680 
(0.02, 0.2 and 2 mg/Kg ip) on carrageenan oedema; *P<0.05, **P<0.01 vs 
vehicle . Dunnett’s test (n = 10). 
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Figure 13. Effects of CGS 21680 (2 mg/kg ip), a selective A2A receptor 
agonist, ZM 241385 (3 mg/kg ip), a selective A2A receptor antagonist, and 
CGS 21680 plus ZM 241385 on carrageenan oedema; *P<0.05, **P<0.01 vs 
vehicle, #P<0.05, ##P<0.01 vs  CGS 21680 plus ZM 241385. Dunnett’s test (n 
= 10).  
 
MPO assay 
MPO activity measured in inflamed paws excised 3 hours after 
carrageenan injection was reduced after treatment with CGS 21680 at 2 
mg/kg ip, compared with control values (Figure14). 
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Figure 14: Effect of CGS 21680 (0.02, 0.2 and 2 mg/kg ip.) on 
myeloperoxidase (MPO) activity of inflamed paws (3 hours after carrageenan 
injection); **P<0.01 vs. vehicle. Dunnett’s test (n = 3). 
 
Western blot 
Western blot analysis performed on paw excised at different time 
following oedema induction, showed an increased A2A protein 
expression starting 1 hour following oedema induction, and peaking 
between 3 and 4 hours.(Figure 15). The increased A2A protein expression 
observed at 3 hours after oedema induction was significantly reduced 
(like control values) following rat treatment with CGS 21680 (2 mg/Kg 
ip.) (Figure 16). 
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Figure 15. Detection of adenosine A2A receptor and optical density analysis in 
inflamed paws;  *P<0.05, **P<0.01 vs vehicle . Dunnett’s test (n = 3).  
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Figure 16. Effect of CGS 21680 (2 mg/kg ip) on the proteic expression of the 
adenosine A2A  in inflamed paws (3 hours after carrageenan injection); 
*P<0.05, **P<0.01 vs vehicle. Dunnett’s test (n = 3).  
 
 Immunohistochemical localization of A2A  
Immunohistochemical analysis showed A2A receptor overall staining on 
vascular endothelium and on dermal fibroblast provided from 
carrageenan-injected paws, compared to no-injected paws. This staining 
was greatly reduced in the case of  paws obtained from CGS 21680-
trated rats (Figure 17). 
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Figure 17: Immunohystochemical localization of A2A receptor paw tissue 
(7µm). The figure represent paw tissue from: A) sham animals; B) vehicle 
treated animals; C) CGS 21680 treated animals. Original magnification is 
10X. 
 
Picro Sirius staining 
Picro Sirius red staining for collagen detection showed that in tissue 
section from inflamed animals, dermal collagen result to be loose 
compared to control paws (not inflamed) and CGS 21680 treated animals 
where dermal elastic fibers appear to be well organized. Moreover, the 
treatment with CGS 21680 enhanced fibroblast infiltration and collagen 
production (Figure 18). 
 
  
 
 
 
 
Figure 18. Sections of paw tissue  stained for picro sirius red for the detection 
of collagen. (A) Paw tissue for sham animals, (B) paw tissue from vehicle 
treated animals, (C) paw tissue from CGS 21680 treated animals. Original 
magnification is 10X.  
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INTERLEUKIN 17A AND THROMBOSIS 
MATERIALS AND METHODS 
Materials  
Recombinant mouse IL-17A was purchased from R&D System 
(Abingdon, UK), reconstituted in 4 mM HCl solution and diluted in 
phosphate saline buffer (PBS) as reported on the certificate of analysis. 
Unless otherwise specified, all the other reagents were from Sigma-
Aldrich Co. (MI, Italy).  
Thrombosis model  
Male Wistar rats (300–350 g; Harlan Nossan, Correzzana, MI, Italy) 
were used for all experiments. Animals were kept under standard 
conditions, with food ad libitum and maintained in a 12 h/12 h light/dark 
cycle at 22 ± 1°C. All the in vivo procedures were in accordance with the 
Italian legislative decree (D.L.) no. 116 of January 27, 1992 and 
associates guidelines in the  European Communities Council Directive of 
November 24, 1986 (8676097ECC).  
Rats were anaesthetized with urethane (10 % w/v; 10 ml/kg ip.) and 
placed on a surgical  table; an arterial thrombus was induced by FeCl3 
application onto the surface of the right carotid artery, as described by 
Kurz et al.. (1990). In brief, following surgery  a piece of filter paper 
(Whatman n°1, 3 x 5 mm) soaked in FeCl3 (from 5 to 35%), or in IL-17A 
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(100 µg/ml), was applied onto the external surface of the right carotid 
artery, for 30 minutes, afterward the paper was removed and the vessel 
left in situ for 60 minutes, to enable thrombus formation. In another set 
of experiments, an IL-17A (100 µg/ml),  or vehicle (saline), soaked 
paper  was applied on the vessel for 30 minutes before applying FeCl3. 
On the basis of preliminary experiments we have chosen a percentage of 
FeCl3 (5%) that induced a partial carotid occlusion. At the end of 60 
minute period, a piece of 2 cm in length of the right carotid artery, and of 
its controlateral (where only vehicles were applied), was removed and 
weighed. Thrombus size was evaluated by the difference in weight 
between  the treated vessel and its controlateral.  In another group of 
animals, the experiment was performed as described above and, vessels 
were removed, rinsed in saline to remove the blood excess, then fixed 
with formalin (4 % v/v) for 24 hours and successively used for 
histological analysis, or removed tissues were immediately frozen in 
liquid nitrogen and successively used for Western blot analysis.   
Western blot analysis 
Tissue samples were defrosted, weighed and homogenized in liquid 
nitrogen. In order to extrapolate proteins, 1 ml of  buffer (β-
glycerophosphate 50 mM; sodium ortovanadate 100µM; MgCl2 2mM; 
EGTA 1mM; DTT 1 mM; PMSF 1mM; Aprotinin 10µg/ml; leupeptin 
10µg/ml) was added to 100 mg of tissue samples. The homogenates were 
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centrifuged at 2500 rpm for 10 minutes at 4°C. The pellets were then 
centrifuged  at 12000 rpm. for 30 minutes at 4°C in order to measure the 
protein content via Bradford assay.  
Proteins were separated by (SDS-PAGE) (8 %); 35 µg of protein were 
applied on the gel and electrophoresed at 90 mV. for 1.30 hour. The 
protein samples were then electroblotted at 250 mA for 1.30 hour onto a 
nitrocellulose membrane. Afterwards, nitrocellulose membrane was 
blocked using a blocking solution containing 5% (w/v) non-fat dry milk, 
0.1% (w/v) BSA and 0.1% (v/v) Tween 20 in PBS, for 2h at room 
temperature. It was then incubated overnight  at 4° C on a shaker with 
anti CD39 (A-16, Santa Cruz)  goat antibody (dilution 1:200). The 
nitrocellulose membrane was washed five times for 25 minutes and then 
incubated with the secondary antibody anti-goat IgG (dilution 1: 2000) 
conjugated with horseradish peroxidase for 2h at room temperature. 
After five washes, the proteins bands were detected using the ECL 
method and analyze with Image Quant 400 GE Healthcare software (GE 
Healtchcare, Italy) as described by the manufacturer.  
 
Morphological analysis 
Samples were processed and embedded in paraffin. Sections (thickness 
5 µm) were then stained for haematoxylin and eosin (H&E) to be 
morphologically analyzed. In all cases, a minimum ≥ 5 sections per 
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animal were analyzed by using a standard light microscope (x 5 and x 10 
objective). In each section the thrombus formation was evaluated by 
calculating the percentage of thrombotic area compared with the total 
area, by using a computerized program (Leica, MI, Italy). Images were 
taken by a Leica DFC320 video-camera (Leica, Milan, Italy) connected 
to a Leica DM RB microscope using the Leica Application Suite 
software V2.4.0. 
 
ELISA and Proteome Profiler Antibody Arrays 
In subsets of experiments, cytokines and chemokines expression from 
whole IL-17-or vehicle-treated carotids was determined. For this purpose 
the carotids were excised, the remaining blood was removed  by washing 
with PBS and immediately frozen in liquid nitrogen before being stored 
at -80°C.  Tissues were placed in a mortar, finely chopped and 
homogenized using liquid nitrogen. The homogenized powder was 
reconstituted with 300 µl of ice-cold lysis buffer (Aprotinin 3.07 µM, 
EDTA 100 mM,  Leupeptin 2.2 µM, Na-deoxycholate 10%, NaCl 150 
mM, NaF 5 mM, NP-40 10%, Ortovanadato 50 µM, PMSF 100 µM, 
Tris-HCl 65 mM) and collected in 1.5 ml eppendorf tubes. Samples were 
frozen and thawed three times in liquid nitrogen and then placed under 
rotation for 30 minutes at 4°C in order to optimize the process of 
homogenization. After spinning at 10.000 rpm to remove cell debris, the 
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supernatants were collected and the total protein concentrations were 
determined by using a Bovine Serum Albumin (BSA) protein assay 
(Biorad, Italy) following the manufacturer’s directions. In order to 
analyze the expression of a wide range of cytokines and chemokines 
after the IL-17 or vehicle application  a proteome profiler antibody array 
(R&D System; Abingdon, UK) was used, according to the 
manufacturer’s instructions. For this purpose 1 ml of homogenized tissue 
from three different rats, treated under the same experimental conditions, 
was used to incubate each membrane on a rocking platform overnight. 
Positive dots were then detected by enhanced chemiluminescence (ECL) 
using Image Quant 400 GE Healthcare software (GE Healtchcare, Italy). 
Aliquots of 50 µl were diluted (1:1) with assay diluents and analyzed for 
the levels of MCP-1 by ELISA according to the manufacturer’s 
instructions (eBioscience, UK). 
 
 RESULTS 
Effect of IL-17A on carotid thrombus model 
A dose responsive curve for FeCl3 was performed to establish the 
percentage of  FeCl3 that we could use for our in vivo model. As showed 
in figure 19, there was a correlation between the effect  of FeCl3 and the 
concentration used. In fact, when 5 % and 15 % of FeCl3 was used a 
partial occlusion of the carotid artery was observed. On the other hand, 
an high concentration of FeCl3 (35%) induced an occlusive thrombus. 
On the light of these preliminary results, we have chosen FeCl3 
concentration of 5% to perform all the subsequent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Thrombus weight (mg) after the application of three different 
concentration of FeCl3 : 5, 15 and 35 % (w/v) respectively. 
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Results obtained (Figure 20) show that the application of IL-17A on rat 
carotid artery determined a small intravascular thrombus with a mass of 
0.35 ± 0.15 mg (one sample t-test, P<0.05) although not significantly 
different compared to the thrombus obtained following the application of 
vehicle. The application of FeCl3 (5 %) caused an intravascular thrombus 
of  0.99 ± 0.2 mg (n=9); however, thrombus mass increased significantly 
when the carotid was pre-treated with IL-17A (100 µg/mL) 30 minutes 
before FeCl3 application (1.94 ± 0.2 mg; n=9. P<0.01). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Thrombus weight after different treatments: vehicle, IL-17, FeCl3, 
and
 
IL-17 plus FeCl3. ** P<0.01 and *** P<0.001 vs vehicle; °° P<0.01 vs 
FeCl3. 
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Western blot analysis 
The western blot analysis  performed on the carotid treated with vehicle 
and IL-17A showed a reduced expression of CD39 protein in IL-17A 
treated animals compare to the vehicle (Figure 21).  
 
Figure 21. Detection of CD39 receptor and optical density analysis in rats 
treated with vehicle and IL-17A respectively.  
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Histological analysis 
Morphological analysis of the vessel section occluded, evidenced that 
the luminal surface of  carotid sections from vehicle group was covered 
by a continuous endothelium. Sections from IL-17A plus FeCl3 treated 
carotids showed an occluding thrombus; furthermore, the endothelium 
appeared damaged and vessel wall thickness extremely reduced (Figure 
22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Histological analysis of haematoxylin and eosin (H&E)-stained 
carotid sections, from : A) vehicle; B) IL-17 alone; C) FeCl3 alone; D) IL-17+ 
FeCl3. Original magnification 5X. 
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Percentage of carotid area of occlusion  
The increased mass of thrombus in the co-administration of FeCl3 and  
IL-17A was confirmed by the measurement in terms of percentage of the 
lumen-vessel occlusion from a computer-assisted planimetry. The 
percentage of occlusive thrombi resulted not significant in IL-17 sections 
compare to vehicle, whereas FeCl3 alone induced an occlusion of 29.9% 
± 5.0 that resulted ∼ 2 fold- increased in IL-17 plus FeCl3- treated 
animals (54.5 % ± 7.0).  
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ELISA and Proteome Profiler Antibody Arrays 
The Figure 23 reported the analysis of the inflammatory proteins in the 
supernatant of vehicle and IL-17A treated carotids. It is possible to 
observe that the interleukin induced the selective production of a specific 
set of chemokines such as CCL2 (MCP-1) compared with vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Elisa Spot obtained from the application of IL-17 (A) and vehicle 
(B) in trombosis model. (PC: positive control; CCL2: MCP-1; IL-17A). 
 
A 
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 CONCLUSION  
Adenosine and inflammation 
Carrageenan – induced rat paw oedema is a classical model of acute 
inflammation, widely used to  identify new therapeutic targets and to test 
the anti-inflammatory potential of new molecules. Aim of the present 
study was to investigate on the role of  A2A adenosine receptor in acute 
inflammation, in vivo.  
The main finding of our research is that following carragenan edema 
induction in rats there is a time dependent increase in A2A receptor 
expression.  
Pharmacological stimulation of A2A receptor, by using the selective A2A 
agonist, CGS21680, prevented edema development in a dose-dependent 
manner. Furthermore, CGS21680 inhibitory effect was prevented by co-
administration with ZM241385.  
Conversely, systemic administration of ZM241385 did not have any 
effect on edema development. These findings confirm that the effect of 
CGS21680 was specific, through A2A receptor stimulation, nonetheless 
A2A activation by endogenous adenosine seems not to offer protection 
against an acute inflammation, since A2A antagonism did not exacerbate 
oedema. This latter finding is in agreement with previous work showing 
that systemic administration of ALT-146e, a selective A2A agonist, 
reduced skin ulceration induced by recurrent ischemia reperfusion in 
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rats, the effect was reverted by the antagonism ZM241385; however, the 
antagonist alone did not exacerbate skin ulceration (Peirce et al., 2001). 
It is known that, among inflammatory cells, neutrophils express A2A 
receptor on their membrane surface; many of antinflammatory effect of 
A2A agonists have been shown to be related to the inhibition of 
neutrophil sequestration (Linden, 2006).  
Moreover, it has been demonstrated that A2A agonist protect from aspirin 
induced gastric lesions by inhibiting neutrophil sequestration into the 
gastric mucosal tissue (Odashima et al., 2006). However, the mechanism 
at the  basis of the antinflammatory effect of adenosine through A2A 
activation has not yet been clarified. Cadiaux and coworkers (2005) have 
shown that following A2A receptor activation on neutrophils there is an 
increased COX2 expression paralleled by increased production of PGE2, 
a prostanoid with antinflammatory properties. Thus, the increased PGE2 
production might be the mechanism by which endogenous adenosine, 
through A2A receptor activation, limits an inflammatory reaction.  
Neutrophis play a pivoltal role in the development of an acute 
inflammation, such as carrageenin edema.  In the present study, as 
marker of neutrophil accumulation, we measured MPO activity in the 
inflamed paw. We found that treatment with CGS21680 significantly 
inhibited the increase in MPO activity into the inflamed tissue 
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confirming that the antinflammatory effect of CGS21680 was associated 
to a reduced neutrophils infiltration.  
Following treatment with CGS21680, edema inhibition was paralleled by 
downregulation of A2A receptor expression on tissues excised. 
Immunohystochemical analysis also showed a reduced immunopositivity 
for A2A receptor on paws obtained from CGS21680 treated rats.  
This finding suggests that in an inflammatory environment there is an 
upregulation of A2A receptor expression,  whose function it to keep down 
inflammation. Further studies are required to better investigate on the 
mechanism underlying the antinflammatory effect mediated by A2A 
activation.  
 
 Interleukin 17A and thrombosis 
To investigate on the role of IL-17A on thrombus formation we used the 
model described by Kurz (Kurz et al., 1990) in which thrombosis is 
induced in rats by topical application of FeCl3 on the exteriorized carotid 
artery.  
We found that topical pre-application of IL-17A on rat carotid artery had 
a synergistic  effect with FeCl3 (5 %); while IL-17A alone caused only a 
small intravascular thrombus. Morphological analysis of the vessel 
section occluded evidenced that the luminal surface of  carotid sections 
from vehicle group was covered by a continuous endothelium; into the 
vascular lumen some aggregates of red blood cells were observed but 
without any fibrin mesh. Sections from IL-17A plus FeCl3 treated 
carotids showed an occluding thrombus; furthermore, the endothelium 
appeared damaged and vessel wall thickness extremely reduced.  
These results suggest that IL-17A has the ability to facilitate thrombus 
formation induced by a minimal stimulus, as FeCl3 at 5 %. There is 
evidence that IL-17A plays a role in vascular inflammation and 
atherothrombosis (von Vietinghoff and Ley, 2010). In vitro, it has been 
shown that IL-17A stimulates C reactive protein expression in human 
coronary artery smooth muscle cells (Patel et al., 2007). As described 
above, C-reactive protein is an important marker of vascular diseases 
playing an active role in atherosclerosis by stimulating chemokine 
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expression, platelet adhesion at the site of vascular damage, 
platelet/leukocyte interaction and also inhibit  the fibrynolitic pathway 
(Danenberg et al., 2007). Thus, clinical evidence showing a correlation 
between IL-17A serum levels and acute coronary syndrome (Cheng et 
al., 2008; Liang et al., 2009), together with experimental data showing 
that IL-17A modifies cellular expression of molecules involved in 
thrombosis (Patel et al., 2007) and also increases ADP-induced platelet 
aggregation  (Maione et al., 2011) has driven the attention of investigator 
to consider this cytokine has possible link between haemostatic disorders 
associate to inflammation.  
Our data show that IL-17A applied alone on carotid causes only a small 
not occlusive thrombus, however, the main effect we observed was that 
IL-17A strongly increased the thrombus induced by a minimal FeCl3 
concentration. The model of FeCl3–induced thrombosis has been shown 
to involve platelets and several component of haemostasis (Broersma et 
al., 1991); thus the effect of IL-17A is consistent with its ability to prime 
platelets for the effect of ADP (Maione et al., 2011). Our preliminary 
results aimed to better investigate on the molecules triggering the pro-
thrombotic effect of IL-17A observed show a possible involvement of 
monocyte chemoattractant  protein (MCP-1). This is a chemokine that is 
expressed by several cells, among which are endothelial cells, smooth 
muscle cells, fibroblasts, monocyte/macrophages. In an inflammatory 
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environment, activated platelets may induce MCP-1 from endothelial 
cells, leading to  monocyte/macrophages chemotaxis and the consequent 
interaction among cells (Charo and Taubman, 2004) included 
platelet/monocyte interactions (Gleissner et al., 2008). We found that 
following exposure to IL-17A there was an increased carotid expression 
of MCP-1.  
We don’t know if MCP-1 is induced by a direct effect IL-17A on 
endothelial cells, or indirectly, from platelets activated by IL-17A. Since 
platelet-induced MCP-1 from endothelial cells is secondary to the 
interaction between CD40L (on activated platelets) and CD40 (on 
endothelium) (Gleissner et al., 2008), it would be interesting to 
investigate whether IL-17A causes externalization of CD40L on platelet 
surface. 
We also observed a reduced expression of CD39 on carotid artery 
following treatment with IL-17A. As described above, CD39 by 
hydrolyzing ATP and ADP to AMP represents a key modulator of 
thrombus formation. It has been shown that the loss of CD39 from 
activated endothelial cells causes platelet sequestration and TF 
upregulation, key events for thrombogenesis (Atkinson et al., 2006). 
Platelets from mice lacking CD39 show an increased response to ADP 
(Enjyoji et al., 1999).  Thus, it could be hypothisized that the first event 
for the prothrombotic effect IL-17A would be a down-regulation of 
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CD39 on endothelial cells and the following  platelet activation; this, in 
turn, would cause increased MCP-1 expression from endothelial cells.  
The mechanicistic bases of pro-thrombotic effect of IL-17A needs 
further investigation; however our findings represent first in vivo 
evidence for a prothrombotic effect of IL-17A and suggest that this 
cytokine might be an important molecule at the interface between 
haemostasis and inflammation. 
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PROTECTIVE EFFECT OF DIMETHYLSULFOXIDE ON ACUTE 
MYOCARDIAL INFARCTION IN RATS 
 
Dimethylsulfoxide (DMSO) is an organic compound that has been shown to 
possess several biological effects, including antioxidant, anti-inflammatory, 
antinociceptive. Chemically, DMSO is an amphipathic molecule widely used as 
solvent in biological studies and as vehicle for drug administration (Santos, et 
al.. 2003; Colucci, et al,. 2008). Since its anti-inflammatory, antinociceptive and 
antioxidant effect, DMSO has been proposed to be therapeutic in several 
disorders, such as gastrointestinal diseases, rheumatologic diseases and for the 
treatment of several manifestations of amyloidosis (Scherbel, et al., 1965; 
Rosestein  et al.,1999; Swanson et al.,1985; Hsieh et al.,1987) Nowadays, its 
therapeutic use has been approved for the treatment of interstitial cystitis, by 
intravescical instillation ( Sant, et al., 1987; Parkin, et al., 1997) and in 
veterinary as analgesic and anti-inflammatory drug (Smith et al., 1998). 
Nonetheless, DMSO is present in topical dermatological preparations for human 
use as active vehicle facilitating drug penetration (Turgwell, et al., 2004). 
The mechanism at the basis of the therapeutic effects of DMSO has not 
yet been elucidated; however, among its several biological activities, 
DMSO has been show to have antioxidant effects (Santos, et al., 2003; 
Colucci, et al., 2008). In addition, experimental studies have shown that 
DMSO reduces intracellular calcium accumulation in different biological 
systems (Zhang, et al., 2004; Choi, et al., 1999; Michel, et al,. 1998; 
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Santos, et al., 2002). However, DMSO - induced relaxation on guinea 
pig and rabbit papillary muscles has been shown to be dependent upon a 
reduced sensitivity to calcium of contractile proteins without affecting 
intracellular calcium concentration (Ogura et al., 1996). Similarly, on 
rabbit detrusor muscle DMSO causes relaxation by decreasing calcium 
sensitivity of the contractile apparatus, an effect that has been shown 
mainly due to the inhibition of  myosin light chain phosphorylation 
(Shiga et al.,2007); this mechanism might be at the basis of its 
therapeutic activity in interstitial cystitis. There is much evidence that 
following ischemia reactive oxygen species produced by an abnormal 
cell metabolism impair myocardial function. Indeed, ischemia is 
followed by calcium overload and prolonged contractile abnormalities. 
Both free radical scavengers and calcium channel blocking agents 
protect myocardial function from ischemic damage (Bolli et al.,1999). 
Cardiac pharmacology of DMSO has also been investigated in several in 
vitro studies demonstrating a protective effect on ischemic damage 
(Shalfer et al., 1983).  
In the attempt to investigate on the effect of adenosine A2A receptor 
agonist, CGS21680, in a model of acute myocardial infarction in rats, we 
came across to an unexpected effect of the vehicle, DMSO, used to 
administered CGS21680 to rats. 
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Thus, on the basis of the literature reported above, showing that DMSO 
has several biological effects, we have sought to investigate the effect of 
DMSO pre-treatment in a model of rat acute myocardial infarction.  
 
  
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL SECTION 
 
 
 
 
  95 
 
METHODS 
Experimental procedure 
All experiments were performed on male Wistar rats (250 – 280 g; 
Harlan Nossan, Italy). Animals were anaesthetized with an 
intraperitoneal injection of a solution of ketamine (100 mg/kg) and 
xylazine (10 mg/kg), placed on a surgical table and artificially ventilated 
through a tracheal cannula connected to a ventilation pump for small 
animals (Ugo Basile, Italy).  
Myocardial infarction was produced by ligation of left anterior 
descending coronary artery (LAD), according to a method previously 
described in Wistar rats ( Guerra, et al., 2006). Briefly, the left side of 
the thorax was opened between the fourth and fifth intercostal space. The 
heart was gently exteriorized and the pericardium dissected out. The left 
anterior descending coronary artery was occluded near its anatomical 
origin by a 5-0 silk suture (Ethicon, Johnson-Johnson) for 90 minutes. 
At the end of the ischemia period, a blood sample was withdrawn from 
abdominal aorta, and the serum was obtained 24 h thereafter following 
centrifugation at 3000 rpm for 15 minutes and then kept at -80 °C until 
the measurement day. Harvested heart following 90 minutes ischemia 
was placed into a Petri dish containing potassium chloride and cut into 5-
6 thick transverse slices from the apex to the basis. Slices were incubated  
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for 30 minutes at 37 °C in a 1 % solution of  2,3,5-triphenyltetraziolium 
chloride (TTC) in 1% phosphate buffered solution (PBS) then washed 
with PBS and stored for three weeks in PBS with 0.01 % sodium azide 
(PBS-A) at 4 °C , as described by Pitts (Pitts et al., 2007). To 
differentiate necrotic (pale) from non necrotic (red) area, each section 
was analyzed by using a computerized image analysis system and  
infarct size was calculated by calculating the percent (%) of necrotic area 
compared to the total area, by using a computerized program (Leica, 
Milan, Italy). 
All animal experiments complied with the Italian D.L. no. 116 of 27 
January 1992 and associates guidelines in the European Communities 
Council Directive of 24 November 1986 (86/609/ECC).  
Treatment with DMSO 
Ischemic animals were divided in three groups: 1) animals that did not 
receive any treatment before ligation; 2) animals treated with DMSO 500 
µl/kg ip., 15’ minutes before the ligation; 3) animals treated with DMSO 
500 µl/kg ip. for three consecutive days, the last injection was given 15 
minutes before the ligation.  Sham animals underwent to the surgical 
intervention without the LAD ligation. 
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Determination of biochemical parameters 
Quantitative determinations of serum cardiac troponin I (cTpI) and  
myoglobin (MYO) were performed by immune enzymatic assays, 
(AxSYM System; Abbott).  
 
Statistical analysis 
All data were expressed as mean ± SEM, of n = 6 – 8, and analyzed with 
the non parametric Kruskal-Wallis test followed by Dunn’s post test by 
using a statistical computer package, GraphPad Prism, v.4.01; a value of 
P<0.05 was considered statistically significant. 
 
  
RESULTS 
Cardiac damage 
Rat treatment with DMSO 500 µg/kg ip. for three consecutive days 
significantly reduced cardiac damage induced by 90 minutes ischemia. 
DMSO given acutely, 15 minutes before LAD ligation, also caused a 
reduction of the damage, but the effect was not statistically significant 
(Table I and Figure 1).  
Biochemical parameters 
Serum levels of cTpI and MYO from ischemic rats were significantly 
reduced by rat treatment with DMSO for three consecutive days. In 
contrast, DMSO given only fifteen minutes before ligation did not have 
any effect on biochemical parameters (Table I).  
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Table I: Effect of rat treatment with two different regimen dosing of DMSO on 
cardiac damage, serum myoglobin (MYO) and serum cardiac troponin (cTPI). 
 
 
 
 
 
Data are the mean ± SEM, * P<0.05 vs. ischemic and †† P< 0.01 vs. sham, Kruskal-
Wallis test followed by Dunn’s post test 
 
 
 
Treatment  Damage % MYO ng/ml cTPI ng/ml 
 
Sham 
 
_  32.25 ± 11.02  
(n = 4) 
  1.25 ± 0.18  
(n=4) 
Ischemic 
 
18.75 ± 4.88 
(n=12) 
46.86 ± 10.35  
(n=7) 
29.35 ± 12.32 
†† 
(n=8)  
Ischemic /DMSO 15 min  8.016 ± 3.23 
(n=10) 
30.44 ± 4.46 
(n=9) 
15.70 ± 4.65 
(n=9) 
Ischemic /DMSO 3 days 
 
 4.46 ± 2.01 * 
(n=8) 
13.75 ± 0.85 * 
(n=4) 
  2.95 ± 1.32 * 
(n=4) 
  100 
 
Figure 1: Cross section of the 2,3,5-triphenyltetrazolium chloride stained heart 
slices. The pale area, indicated by arrows, represents infarction area of the anterior 
wall of the left ventricle; (A) sham, (B) ischemic, (C) ischemic plus DMSO 500 
µl/Kg 15 minutes before, and (D) ischemic plus DMSO 500 µl/Kg for 3 days (x10 
photo ocular; x 6.4, magnification charger). 
 
 
B 
 
A 
 
D 
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 CONCLUSION 
Here, we investigated on the effect of DMSO in a model of rat acute 
myocardial infarction. Our main result is that DMSO reduced 
myocardial damage following LAD ligation, accordingly to previous 
results on its protective effect on cerebral ischemia (Shimizu et al.,1997), 
on hepatic ischemia reperfusion injury (Sahin, et al., 2004) and on in 
vitro cardiac ischemia (Shalfer, et al., 1983). The mechanism at the basis 
of this protective effect is not known; it is known that DMSO readily 
penetrates cell membranes; inside the cells its effect on ischemic damage 
might be attributed to an antioxidant effect given its properties as free 
radical scavenger but also to an effect of ion exchange through cell 
membranes and thus on cell excitation (Santos et al., 2003; Colucci, et 
al,. 2008). An early study performed on perfused rat hearts demonstrates 
that DMSO protects from oxygen induced cell damage following 
reperfusion and also reduces contractile force of heart caused by hypoxic 
contracture (Ganote, et al., 1982), suggesting that this effect could be 
dependent upon an action of DMSO directly on contractile proteins or, 
indirectly, on calcium metabolism. However, other works demonstrate 
that DMSO does not alter ion exchange through cell membranes but has 
negative inotropic effect probably due to an inhibition of myofilament to 
calcium responsiveness (Ogura et al., 1996). In our study, the beneficial 
effect on cardiac function is confirmed by  the reduction of serum levels 
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of myoglobin and cTPI whose increasing levels following ischemia 
represent contractile protein damage.  
In conclusion, here we show for the first time a protective effect for DMSO on 
an in vivo model of rat acute myocardial ischemia, although further studies are 
required to define the mechanism at the basis of this effect, we think that our 
work contributes to delineate the pharmacological profile of this neglected 
compound.  
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